Living Cell Technologies Ltd. (LVCLF)
OTHER OTC:LVCLF
Want to see LVCLF full AI Analyst Report?
LVCLF Stock Chart & Stats
$0.01
>-$0.01(-68.75%)
At close: 4:00 PM EST
$0.01
>-$0.01(-68.75%)
Day’s Range― - ―
52-Week Range― - ―
Previous CloseN/A
Volume10.00K
Average Volume (3M)N/A
Market Cap
$15.87M
Enterprise Value$17.71M
Total Cash (Recent Filing)$1.88M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta3.37
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding2,023,070,200
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.79
Price to Sales (P/S)0.00
P/FCF Ratio-10.74
Enterprise Value/Market Cap1.12
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-8.67
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetAbsence of debt materially lowers fixed financial obligations and interest expense, preserving runway and strategic optionality. For a clinical-stage biotech, low leverage reduces bankruptcy risk and makes future R&D funding or partnership deals less constrained over the next 2-6 months.
Clinical-stage Cell Therapy FocusA focused R&D platform in encapsulated cell therapies targets chronic, high-unmet-need diseases where proprietary technology can create durable competitive advantages. Clinical-stage programs increase long-term value optionality via partnerships, licensing or M&A rather than catch-up commercial competition.
Improving Loss/cash-burn TrendNarrowing net losses and reduced cash burn indicate better cost control or program milestones that lower funding pressure. While still reliant on external capital, improving trends reduce short-term dilution risk and enhance the company’s ability to sustain R&D activity in the medium term.
Bears Say
No Meaningful RevenueLack of recurring commercial revenue leaves the company dependent on capital markets or partners to fund operations. For a clinical-stage biotech this extends the time to commercialization and increases execution and financing risk over the next several quarters.
Persistent Negative Cash FlowConsistent negative operating and free cash flow erodes cash reserves and forces periodic financing, which dilutes shareholders and can restrict program spending. Persistent burn undermines ability to scale trials or seize partnership opportunities without external funding.
Declining Equity And AssetsEroding equity and a shrinking asset base reflect cumulative losses and reduce balance-sheet flexibility. This limits options for non-dilutive financing, weakens creditworthiness if debt is later required, and signals structural funding challenges absent revenue or major partnering.
Living Cell Technologies News
LVCLF FAQ
What was Living Cell Technologies Ltd.’s price range in the past 12 months?
Currently, no data Available
What is Living Cell Technologies Ltd.’s market cap?
Living Cell Technologies Ltd.’s market cap is $15.87M.
When is Living Cell Technologies Ltd.’s upcoming earnings report date?
Living Cell Technologies Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 130 days.
How were Living Cell Technologies Ltd.’s earnings last quarter?
Living Cell Technologies Ltd. released its earnings results on Feb 27, 2026. The company reported $0 earnings per share for the quarter, the consensus estimate of N/A by $0.
Is Living Cell Technologies Ltd. overvalued?
According to Wall Street analysts Living Cell Technologies Ltd.’s price is currently Overvalued.
Does Living Cell Technologies Ltd. pay dividends?
Living Cell Technologies Ltd. does not currently pay dividends.
What is Living Cell Technologies Ltd.’s EPS estimate?
Living Cell Technologies Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Living Cell Technologies Ltd. have?
Living Cell Technologies Ltd. has 2,023,070,200 shares outstanding.
What happened to Living Cell Technologies Ltd.’s price movement after its last earnings report?
Living Cell Technologies Ltd. reported an EPS of $0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Living Cell Technologies Ltd.?
Currently, no hedge funds are holding shares in LVCLF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Living Cell Technologies Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-49.25%
Trailing 12-Months
Asset Growth
-15.04%
Trailing 12-Months
Company Description
Living Cell Technologies Ltd.
Algorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate made up of donepezil and cannabidiol for the treatment of dementia, including Alzheimer's disease; AI-168, a novel combination drug candidate made up of a cannabinoid and an off-patent pharmaceutical ingredient for the treatment of cardiovascular disease, such as hypertension; and NTCELL, an alginate coated capsule product for the treatment of Parkinson's disease. It is also developing AlgaraeOS in partnership with the University of New South Wales, a drug discovery platform that uses artificial intelligence protocols and big data analytics for drug discovery and development. The company was formerly known as Living Cell Technologies Limited and changed its name to Algorae Pharmaceuticals Limited in September 2023. Algorae Pharmaceuticals Limited was founded in 1987 and is based in Melbourne, Australia.
Cynata Therapeutics Limited
―
Mesoblast Limited
―
Orthocell Ltd
―
Tissue Repair Ltd
―
Regeneus Ltd.
―